Shepard B, Trower C, Hendrickson S. Toxic Injury to the Gastrointestinal Tract After Ipilimumab Therapy for Advanced Melanoma. J Am Osteopath Assoc 2018;118(1):40–44. doi: https://doi.org/10.7556/jaoa.2018.007.
Download citation file:
Ipilimumab, cytotoxic T-lymphocyte-associated protein 4–blocking antibody, is known to precipitate tissue-specific immune-related adverse events. The second most common site for immune-related adverse events is the gastrointestinal tract, with toxic injury resulting in diarrhea, colitis, and enterocolitis. In the present case, a woman who received ipilimumab 2 weeks prior was found to have severe, diffuse corticosteroid-refractory gastrointestinal tract toxic injury affecting the stomach, small bowel, and colon.
This PDF is available to Subscribers Only
View Article Abstract & Purchase Options